Selective inhibition of monocyte chemoattractant protein-1 gene expressionin human embryonal kidney cells by specific triple helix-forming oligonucleotides
P. Marchand et al., Selective inhibition of monocyte chemoattractant protein-1 gene expressionin human embryonal kidney cells by specific triple helix-forming oligonucleotides, J IMMUNOL, 164(4), 2000, pp. 2070-2076
Monocyte chemoattractant protein-1 (MCP-1) is a chemokine that is expressed
by a variety of tissue cells in response to inflammatory stimuli, such as
IL-1 beta, TNF-alpha, and IFN-gamma. A major function of MCP-1 is the recru
itment and activation of monocytes and T lymphocytes, Overexpression of MCP
-1 has been implicated in a number of diseases, including glomerulonephriti
s and rheumatoid arthritis, indicating that the modulation of MCP-1 activit
y and/or expression is a desired therapeutic strategy, In the present study
, our aim was to test whether the MCP-1 expression could be inhibited at th
e transcriptional level using triple helix-forming oligonucleotides (TFOs),
We designed a TFO targeted to the SP-1 binding site in the human MCP-1 gen
e promoter. Gel mobility shift assays demonstrated that the phosphodiester
TFO formed a sequence-specific tripler with its dsDNA target with an EC50 o
f similar to 1.9 x 10(-7) M, The corresponding phosphorothioated oligonucle
otide was also effective in this assay with an 8-fold higher EC50 value. Bi
nding of the TFO to the target DNA prevented the binding of rSP-1 and of nu
clear proteins in vitro. The TFO could also partially inhibit endogenous MC
P-1 gene expression in cultured human embryonic kidney cells. Treatment of
TNF-alpha-stimulated human embryonic kidney 293 cells with the TFO inhibite
d the secretion of MCP-1 in a dose-dependent manner (up to 45% at 5 mu M ol
igonucleotide), The inhibition of MCP secretion was caused at the level of
gene transcription, because MCP-1 mRNA levels in oligonucleotide-treated ce
lls were also decreased by similar to 40%, The Journal of Immunology, 2000,
164: 2070-2076.